399 related articles for article (PubMed ID: 20086023)
1. Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study.
Mesaros S; Rocca M; Sormani M; Valsasina P; Markowitz C; De Stefano N; Montalban X; Barkhof F; Ranjeva J; Sailer M; Kappos L; Comi G; Filippi M
Mult Scler; 2010 Mar; 16(3):325-31. PubMed ID: 20086023
[TBL] [Abstract][Full Text] [Related]
2. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.
Rovaris M; Agosta F; Sormani MP; Inglese M; Martinelli V; Comi G; Filippi M
Brain; 2003 Oct; 126(Pt 10):2323-32. PubMed ID: 12937086
[TBL] [Abstract][Full Text] [Related]
3. Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis.
Oreja-Guevara C; Charil A; Caputo D; Cavarretta R; Sormani MP; Filippi M
Arch Neurol; 2006 May; 63(5):736-40. PubMed ID: 16682543
[TBL] [Abstract][Full Text] [Related]
4. Magnetization transfer can predict clinical evolution in patients with multiple sclerosis.
Santos AC; Narayanan S; de Stefano N; Tartaglia MC; Francis SJ; Arnaoutelis R; Caramanos Z; Antel JP; Pike GB; Arnold DL
J Neurol; 2002 Jun; 249(6):662-8. PubMed ID: 12111296
[TBL] [Abstract][Full Text] [Related]
5. Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.
Rudick RA; Lee JC; Simon J; Fisher E
Ann Neurol; 2006 Aug; 60(2):236-42. PubMed ID: 16786526
[TBL] [Abstract][Full Text] [Related]
6. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis.
De Stefano N; Battaglini M; Stromillo ML; Zipoli V; Bartolozzi ML; Guidi L; Siracusa G; Portaccio E; Giorgio A; Sorbi S; Federico A; Amato MP
Brain; 2006 Aug; 129(Pt 8):2008-16. PubMed ID: 16815879
[TBL] [Abstract][Full Text] [Related]
7. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis.
Agosta F; Rovaris M; Pagani E; Sormani MP; Comi G; Filippi M
Brain; 2006 Oct; 129(Pt 10):2620-7. PubMed ID: 16951409
[TBL] [Abstract][Full Text] [Related]
8. Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study.
Oreja-Guevara C; Rovaris M; Iannucci G; Valsasina P; Caputo D; Cavarretta R; Sormani MP; Ferrante P; Comi G; Filippi M
Arch Neurol; 2005 Apr; 62(4):578-84. PubMed ID: 15824256
[TBL] [Abstract][Full Text] [Related]
9. TI-relaxation time changes over five years in relapsing-remitting multiple sclerosis.
Papadopoulos K; Tozer DJ; Fisniku L; Altmann DR; Davies G; Rashid W; Thompson AJ; Miller DH; Chard DT
Mult Scler; 2010 Apr; 16(4):427-33. PubMed ID: 20086026
[TBL] [Abstract][Full Text] [Related]
10. Investigation of quantitative magnetisation transfer parameters of lesions and normal appearing white matter in multiple sclerosis.
Cercignani M; Basile B; Spanò B; Comanducci G; Fasano F; Caltagirone C; Nocentini U; Bozzali M
NMR Biomed; 2009 Jul; 22(6):646-53. PubMed ID: 19322806
[TBL] [Abstract][Full Text] [Related]
11. [Diffusion tensor imaging of the normal-appearing brain tissue in relapsing-remitting multiple sclerosis].
Yu CS; Li KC; Lin FC; Jiang TZ; Sun H; Chen B
Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1260-4. PubMed ID: 16796886
[TBL] [Abstract][Full Text] [Related]
12. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
Agosta F; Absinta M; Sormani MP; Ghezzi A; Bertolotto A; Montanari E; Comi G; Filippi M
Brain; 2007 Aug; 130(Pt 8):2211-9. PubMed ID: 17535835
[TBL] [Abstract][Full Text] [Related]
13. Association between MRI parameters and the MS severity scale: a 12 year follow-up study.
Minneboo A; Uitdehaag BM; Jongen P; Vrenken H; Knol Dl; van Walderveen MA; Polman CH; Castelijns JA; Barkhof F
Mult Scler; 2009 May; 15(5):632-7. PubMed ID: 19389751
[TBL] [Abstract][Full Text] [Related]
14. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
[TBL] [Abstract][Full Text] [Related]
15. Absence of diffuse cervical cord tissue damage in early, non-disabling relapsing-remitting MS: a preliminary study.
Rovaris M; Judica E; Ceccarelli A; Ghezzi A; Martinelli V; Comi G; Filippi M
Mult Scler; 2008 Jul; 14(6):853-6. PubMed ID: 18611991
[TBL] [Abstract][Full Text] [Related]
16. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
17. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G; Filippi M; Wolinsky JS
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[TBL] [Abstract][Full Text] [Related]
18. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
[TBL] [Abstract][Full Text] [Related]
19. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
Boster A; Hreha S; Berger JR; Bao F; Penmesta R; Tselis A; Endress C; Zak I; Perumal J; Caon C; Vazquez J; Tyler KL; Racke MK; Millis S; Khan O
Arch Neurol; 2009 May; 66(5):593-9. PubMed ID: 19433659
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
